文献速递胸部肿瘤消化系统肿瘤

阿替利珠单抗1200毫克联合贝伐珠单抗15毫克每千克:基于科学还是仅出于收入考虑

Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
PubMed 文献 · Eur J Cancer · 2023-09-20

本文讨论肿瘤药物剂量优化的重要性,以美国食品药品监督管理局的Project Optimus倡议为例,并关注抗癌药物价格、可负担性和可及性问题。作者以阿替利珠单抗联合贝伐珠单抗为例,该方案在多个国家获批用于非小细胞肺癌和肝细胞癌,结论是该方案的成本可降低超过80%,患者、处方者、支付方和政策制定者应考虑这一机会。

要点

  • 肿瘤药物剂量优化日益重要,美国食品药品监督管理局的Project Optimus倡议与其他国家的类似倡议一致。
  • 多种利益相关方对抗癌药物价格、可负担性和可及性提出担忧,尤其影响政府支付方及中低收入国家的患者和医生。
  • 作者以阿替利珠单抗联合贝伐珠单抗为例,结论是该方案成本可降低超过80%,应考虑此机会。

核心结论

  • 阿替利珠单抗联合贝伐珠单抗方案的成本可降低超过80%,患者、处方者、支付方和政策制定者应考虑这一机会。

研究设计与样本

  • 本文为讨论性文章,以美国食品药品监督管理局的Project Optimus倡议为背景,讨论肿瘤药物剂量优化问题,并以阿替利珠单抗联合贝伐珠单抗为例进行说明。

主要发现

  • 抗癌药物历史上按最大耐受剂量获批,因此有必要质疑较低剂量是否同等有效、能否以较低剂量给药从而减少患者毒性并降低患者和支付方成本。
  • 阿替利珠单抗联合贝伐珠单抗在多个国家获批用于非小细胞肺癌和肝细胞癌。
  • 作者结论为该方案成本可降低超过80%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dose optimisation is increasingly important in oncology, as exemplified by the US Food and Drug Administration's Project Optimus initiative, which is aligned with similar initiatives in other countries. In parallel, multiple stakeholders have raised concerns about anticancer drug prices, affordability, and access. This is of particular concern to government payers as well as patients and physicians in low- and middle-income countries. As anticancer drugs have historically been approved at the maximally tolerated dose, it is now highly relevant to question whether lower doses are equally effective and can be delivered at lower doses, resulting in less toxicity for patients, and lower costs for patients and payers. We illustrate this opportunity by discussing the combination of atezolizumab and bevacizumab, approved in multiple countries for both non-small cell lung cancer and hepatocellular cancer. Our conclusion is that the cost of this regimen can be reduced by more than 80%, an opportunity that should be considered by patients, prescribers, payers, and policymakers.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ratain MJ, Strohbehn GW. Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues? Eur J Cancer. 2023. PMID: 37806256. doi:10.1016/j.ejca.2023.113349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。